Your browser doesn't support javascript.
loading
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study.
Perumal, Jai; Balabanov, Roumen; Su, Ray; Chang, Roger; Balcer, Laura; Galetta, Steven; Campagnolo, Denise I; Avila, Robin; Lee, Lily; Rutledge, Danette; Fox, Robert J.
Affiliation
  • Perumal J; Department of Neurology and Neuroscience, Weill Cornell Medical College, Cornell University, 1300 York Avenue, New York, NY, 10065, USA. jaisperumal@gmail.com.
  • Balabanov R; Department of Neurology, Northwestern University, Chicago, IL, USA.
  • Su R; Inari Medical, Irvine, CA, USA.
  • Chang R; Biogen, Cambridge, MA, USA.
  • Balcer L; Department of Neurology, New York University School of Medicine, New York, NY, USA.
  • Galetta S; Department of Neurology, New York University School of Medicine, New York, NY, USA.
  • Campagnolo DI; Biogen, Cambridge, MA, USA.
  • Avila R; Biogen, Cambridge, MA, USA.
  • Lee L; TG Therapeutics, New York, NY, USA.
  • Rutledge D; Biogen, Cambridge, MA, USA.
  • Fox RJ; Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, USA.
Adv Ther ; 38(7): 3743-3744, 2021 Jul.
Article in En | MEDLINE | ID: mdl-34159559
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Adv Ther Year: 2021 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Adv Ther Year: 2021 Document type: Article